In  premenopausal women having symptomatic  adenomyosis, both  single  trimonthly  (10.8  mg)  and  monthly  (3.6  mg)  administration  of  goserelin  for  three  months  considerably relieved  dysmenorrhea  symptoms, decreased  uterine volume, improved  anemia,  and  minimized  CA125  levels, according to a prospective cohort study. In premenopausal patients suffering from adenomyosis, the clinical effectiveness and safety of Goserelin taken trimonthly versus Goserelin received monthly were compared by researchers.

A total of 139 females who reported either menorrhagia or dysmenorrhea were enrolled.  Participants were segregated to receive either single subcutaneous injection of goserelin 10.8 mg (n = 70) or monthly subcutaneous goserelin 3.6 mg (n = 69) for three months. After 12 weeks, a follow-up visit was performed at the outpatient department.

Overall, 130 individuals, incorporating 68 and 62 subjects respectively in the Goserelin 10.8 mg (n = 70) and 3.6 mg (n = 69) groups finished the study. In both the intervention groups, a considerable rise in hemoglobin levels and a substantial decline in the cancer antigen 125 (CA125) values, uterine volume, and dysmenorrhea (Numerical Rating Scale [NRS]) score were observed. The two groups did not considerably differ from one another. Compared to the 10.8 mg group, the sum of adverse event scores was somewhat greater in the Goserelin 3.6 mg group.

Therefore, trimonthly  10.8 mg Goserelin  appears to be  an  alternative  regimen  that  is  more  convenient  for  premenopausal females with adenomyosis,  potentially  aiding  to improve  compliance.  Furthermore,  it  is  less  expensive  and  effective  in  minimizing   patient   outpatient   visits,  that will aid to decrease  patient-associated medical care costs and clinician burden on physicians.